Answers are grounded in this paper and cite their sources.
Dr. Dago is Assistant Professor of Psychiatry, Feinberg School of Medicine, Northwestern University, 446 East Ontario, Suite 7-100, Chicago, IL 60611; E-mail: [email protected]. Dr. Dago has disclosed that he is/was a member of the speakers bureau for Bristol-Myers Squibb, Eli Lilly, AstraZeneca, and Wyeth. Dr. Dago has disclosed that the use of the selegine transdermal system for treatment of atypical depression and treatment-resistant depression has not been approved by the U.S. Food and Drug Administration. Lippincott CME Institute, Inc. has identified and resolved all faculty conflicts of interest regarding this educational activity.
No takes yet. Share an insight, caveat, or question.
Pedro Luis Dago (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: